Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 25

1.

Circulating Type-1 Anti-Tumor CD4(+) T Cells are Preferentially Pro-Apoptotic in Cancer Patients.

Wesa AK, Mandic M, Taylor JL, Moschos S, Kirkwood JM, Kwok WW, Finke JH, Storkus WJ.

Front Oncol. 2014 Sep 29;4:266. doi: 10.3389/fonc.2014.00266. eCollection 2014.

2.

A novel probe for the non-invasive detection of tumor-associated inflammation.

Balducci A, Wen Y, Zhang Y, Helfer BM, Hitchens TK, Meng WS, Wesa AK, Janjic JM.

Oncoimmunology. 2013 Feb 1;2(2):e23034.

3.

¹⁹F MRI tracer preserves in vitro and in vivo properties of hematopoietic stem cells.

Helfer BM, Balducci A, Sadeghi Z, O'Hanlon C, Hijaz A, Flask CA, Wesa A.

Cell Transplant. 2013;22(1):87-97. doi: 10.3727/096368912X653174. Epub 2012 Aug 2.

4.

Visualizing arthritic inflammation and therapeutic response by fluorine-19 magnetic resonance imaging (19F MRI).

Balducci A, Helfer BM, Ahrens ET, O'Hanlon CF 3rd, Wesa AK.

J Inflamm (Lond). 2012 Jun 21;9(1):24. doi: 10.1186/1476-9255-9-24.

5.

Intralesional delivery of dendritic cells engineered to express T-bet promotes protective type 1 immunity and the normalization of the tumor microenvironment.

Qu Y, Chen L, Pardee AD, Taylor JL, Wesa AK, Storkus WJ.

J Immunol. 2010 Sep 1;185(5):2895-902. doi: 10.4049/jimmunol.1001294. Epub 2010 Jul 30.

6.

Integrating costimulatory agonists to optimize immune-based cancer therapies.

Pardee AD, Wesa AK, Storkus WJ.

Immunotherapy. 2009 Mar;1(2):249-64. doi: 10.2217/1750743X.1.2.249. Review.

7.

DC expressing transgene Foxp3 are regulatory APC.

Lipscomb MW, Taylor JL, Goldbach CJ, Watkins SC, Wesa AK, Storkus WJ.

Eur J Immunol. 2010 Feb;40(2):480-93. doi: 10.1002/eji.200939667.

8.

Ectopic T-bet expression licenses dendritic cells for IL-12-independent priming of type 1 T cells in vitro.

Lipscomb MW, Chen L, Taylor JL, Goldbach C, Watkins SC, Kalinski P, Butterfield LH, Wesa AK, Storkus WJ.

J Immunol. 2009 Dec 1;183(11):7250-8. doi: 10.4049/jimmunol.0901477. Epub 2009 Nov 13.

9.

Heat shock protein 90 inhibitor 17-dimethylaminoethylamino-17-demethoxygeldanamycin enhances EphA2+ tumor cell recognition by specific CD8+ T cells.

Kawabe M, Mandic M, Taylor JL, Vasquez CA, Wesa AK, Neckers LM, Storkus WJ.

Cancer Res. 2009 Sep 1;69(17):6995-7003. doi: 10.1158/0008-5472.CAN-08-4511. Epub 2009 Aug 18.

10.

Enhancement in specific CD8+ T cell recognition of EphA2+ tumors in vitro and in vivo after treatment with ligand agonists.

Wesa AK, Herrem CJ, Mandic M, Taylor JL, Vasquez C, Kawabe M, Tatsumi T, Leibowitz MS, Finke JH, Bukowski RM, Bruckheimer E, Kinch MS, Storkus WJ.

J Immunol. 2008 Dec 1;181(11):7721-7.

11.

CD8+ T-cell responses against hemoglobin-beta prevent solid tumor growth.

Komita H, Zhao X, Taylor JL, Sparvero LJ, Amoscato AA, Alber S, Watkins SC, Pardee AD, Wesa AK, Storkus WJ.

Cancer Res. 2008 Oct 1;68(19):8076-84. doi: 10.1158/0008-5472.CAN-08-0387.

12.

Interferon-alpha (IFN-alpha)-conditioned DC preferentially stimulate type-1 and limit Treg-type in vitro T-cell responses from RCC patients.

Gigante M, Mandic M, Wesa AK, Cavalcanti E, Dambrosio M, Mancini V, Battaglia M, Gesualdo L, Storkus WJ, Ranieri E.

J Immunother. 2008 Apr;31(3):254-62. doi: 10.1097/CJI.0b013e318167b023.

PMID:
18317362
13.

Improving immunotherapy by conditionally enhancing MHC class I presentation of tumor antigen-derived Peptide epitopes.

Storkus WJ, Herrem C, Kawabe M, Cohen PA, Bukowski RM, Finke JH, Wesa AK.

Crit Rev Immunol. 2007;27(5):485-93. Review.

PMID:
18197809
14.

Killer dendritic cells: mechanisms of action and therapeutic implications for cancer.

Wesa AK, Storkus WJ.

Cell Death Differ. 2008 Jan;15(1):51-7. Epub 2007 Oct 19. Review.

15.

Interleukin-12: biological properties and clinical application.

Del Vecchio M, Bajetta E, Canova S, Lotze MT, Wesa A, Parmiani G, Anichini A.

Clin Cancer Res. 2007 Aug 15;13(16):4677-85. Review.

16.

Preferential expression of very late antigen-4 on type 1 CTL cells plays a critical role in trafficking into central nervous system tumors.

Sasaki K, Zhu X, Vasquez C, Nishimura F, Dusak JE, Huang J, Fujita M, Wesa A, Potter DM, Walker PR, Storkus WJ, Okada H.

Cancer Res. 2007 Jul 1;67(13):6451-8.

17.
18.

Effect of renal cell carcinomas on the development of type 1 T-cell responses.

Rayman P, Wesa AK, Richmond AL, Das T, Biswas K, Raval G, Storkus WJ, Tannenbaum C, Novick A, Bukowski R, Finke J.

Clin Cancer Res. 2004 Sep 15;10(18 Pt 2):6360S-6S.

19.

alpha-type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity.

Mailliard RB, Wankowicz-Kalinska A, Cai Q, Wesa A, Hilkens CM, Kapsenberg ML, Kirkwood JM, Storkus WJ, Kalinski P.

Cancer Res. 2004 Sep 1;64(17):5934-7.

20.

4-1BB-ligand is regulated on human dendritic cells and induces the production of IL-12.

Laderach D, Wesa A, Galy A.

Cell Immunol. 2003 Nov;226(1):37-44.

PMID:
14746806
21.

GPL, a novel cytokine receptor related to GP130 and leukemia inhibitory factor receptor.

Diveu C, Lelièvre E, Perret D, Lak-Hal AH, Froger J, Guillet C, Chevalier S, Rousseau F, Wesa A, Preisser L, Chabbert M, Gauchat JF, Galy A, Gascan H, Morel A.

J Biol Chem. 2003 Dec 12;278(50):49850-9. Epub 2003 Sep 22.

23.

IL-1 beta induces dendritic cells to produce IL-12.

Wesa AK, Galy A.

Int Immunol. 2001 Aug;13(8):1053-61.

PMID:
11470775
24.

Supplemental Content

Support Center